Panitumumab side effects: what 15,571 FDA adverse event reports show
Drug class
Epidermal Growth Factor Receptor Antagonist
Brand names
Vectibix
Who reports
15,571 reports · 87% serious · 2,610 with death outcome · 38% female
Used for
Vectibix is an epidermal growth factor receptor (EGFR) antagonist indicated for the treatment of: Adult patients with wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test) Metastatic Colorectal Cancer (mCRC): In combination with FOLFOX for first-line treatment.
What it is
Panitumumab is an epidermal growth factor receptor (EGFR) antagonist for intravenous use. Panitumumab is a human IgG2 kappa monoclonal antibody with an approximate molecular weight of 147 kDa that is produced in genetically engineered mammalian (Chinese hamster ovary) cells.
Boxed warning
DERMATOLOGIC TOXICITY Dermatologic Toxicity: Dermatologic toxicities occurred in 90% of patients and were severe (NCI-CTC Grade 3 and higher) in 15% of patients receiving Vectibix monotherapy [see Dosage and Administration (2.3) , Warnings and Precautions (5.1) and Adverse Reactions (6.1) ] .
Causality screen of the 40 strongest signals
What the badges mean
- Labeled — boxed warning The term (or its clinical synonym) appears in the FDA boxed warning: causality is regulator-recognised and considered serious.
- Labeled adverse reaction The exact term appears in the label's warnings or adverse-reactions sections: a known, expected effect. The FAERS signal confirms the label rather than discovering anything.
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Likely indication confounding The term appears in the label's indications: reports probably describe the disease being treated (or its progression), not a drug effect. Classic confounding by indication.
- Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only and flags pairs whose reports are unusually skewed by sex or come mostly from consumers rather than clinicians. 980 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Trichomegaly | 35 | 815.3 535.4–1,241.6ROR 817.1 · χ² 17,135 / p <1e-300 | 395.8 EB05 297.5 · IC025 +5.4 3/3 methods agree | Not in label — unassessed | serious n=33 · 94% clinician | not reported in cached trials |
| Depilation | 11 | 730.3 350.0–1,523.8ROR 730.8 · χ² 4,708 / p <1e-300 | 259.4 EB05 154.5 · IC025 +3.4 3/3 methods agree | Not in label — unassessed | serious n=11 | not reported in cached trials |
| Colorectal cancer metastatic | 768 | 684.4 628.2–745.6ROR 719.8 · χ² 345,403 / p <1e-300 | 446.9 EB05 421.0 · IC025 +8.3 3/3 methods agree | Likely indication confounding term in indications | serious n=768 | NCT00339183: 9/587 (1.5%) on Panitumumab (serious AE) |
| Colorectal cancer recurrent | 36 | 525.3 357.2–772.4ROR 526.5 · χ² 13,125 / p <1e-300 | 313.8 EB05 236.8 · IC025 +5.4 3/3 methods agree | Labeled (related wording) related wording | serious n=36 · ♀ 12% (drug 38%) | not reported in cached trials |
| Dermatitis acneiform | 1,048 | 282.6 264.9–301.5ROR 302.9 · χ² 242,298 / p <1e-300 | 232.2 EB05 220.6 · IC025 +7.6 3/3 methods agree | Labeled adverse reaction exact term | serious n=965 · 95% clinician | NCT02089737: 14/1,831 (0.8%) on Panitumumab (serious AE) |
| Skin toxicity | 906 | 261.5 244.0–280.3ROR 277.6 · χ² 196,266 / p <1e-300 | 217.6 EB05 206.0 · IC025 +7.5 3/3 methods agree | Labeled adverse reaction exact term | serious n=840 | NCT00339183: 3/587 (0.5%) on Panitumumab (serious AE) |
| Xeroderma | 43 | 254.9 184.0–353.1ROR 255.6 · χ² 8,911 / p <1e-300 | 195.5 EB05 151.2 · IC025 +5.4 3/3 methods agree | Labeled adverse reaction exact term | serious n=42 · ♀ 62% (drug 38%) · 100% clinician | not reported in cached trials |
| Paronychia | 580 | 208.6 191.4–227.4ROR 216.7 · χ² 103,421 / p <1e-300 | 179.4 EB05 167.5 · IC025 +7.2 3/3 methods agree | Labeled — boxed warning exact term | serious n=545 · 95% clinician | NCT02089737: 5/1,831 (0.3%) on Panitumumab (serious AE) |
| Rectal cancer metastatic | 41 | 180.9 130.6–250.5ROR 181.3 · χ² 6,297 / p <1e-300 | 148.4 EB05 114.1 · IC025 +5.3 3/3 methods agree | Likely indication confounding term in indications | serious n=41 · 100% clinician | NCT00339183: 9/587 (1.5%) on Panitumumab (serious AE) |
| Transient aphasia | 13 | 148.8 83.9–263.9ROR 148.9 · χ² 1,586 / p <1e-300 | 112.3 EB05 69.8 · IC025 +3.6 3/3 methods agree | Not in label — unassessed | serious n=13 | not reported in cached trials |
| Hepatectomy | 28 | 136.2 92.3–200.9ROR 136.4 · χ² 3,286 / p <1e-300 | 114.2 EB05 82.9 · IC025 +4.7 3/3 methods agree | Not in label — unassessed | serious n=28 · 93% clinician | not reported in cached trials |
| Colorectal adenocarcinoma | 17 | 110.6 67.5–181.4ROR 110.8 · χ² 1,605 / p <1e-300 | 92.0 EB05 60.8 · IC025 +3.9 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=17 | not reported in cached trials |
| Mucocutaneous rash | 11 | 105.8 57.3–195.5ROR 105.9 · χ² 963 / p 1e-211 | 84.2 EB05 50.2 · IC025 +3.2 3/3 methods agree | Labeled (related wording) related wording | serious n=10 | not reported in cached trials |
| Adenocarcinoma metastatic | 14 | 103.8 60.3–178.9ROR 103.9 · χ² 1,229 / p 2e-269 | 85.5 EB05 54.1 · IC025 +3.6 3/3 methods agree | Not in label — unassessed | serious n=14 | not reported in cached trials |
| Eyelash changes | 12 | 101.5 56.4–182.5ROR 101.6 · χ² 1,018 / p 1e-223 | 82.4 EB05 50.2 · IC025 +3.3 3/3 methods agree | Not in label — unassessed | serious n=12 | not reported in cached trials |
| Nail bed inflammation | 21 | 95.2 61.1–148.1ROR 95.3 · χ² 1,739 / p <1e-300 | 82.4 EB05 56.9 · IC025 +4.1 3/3 methods agree | Labeled (related wording) related wording | serious n=19 | not reported in cached trials |
| Colon cancer recurrent | 17 | 89.2 54.6–145.8ROR 89.3 · χ² 1,308 / p 1e-286 | 76.7 EB05 50.7 · IC025 +3.8 3/3 methods agree | Not in label — unassessed | serious n=17 | not reported in cached trials |
| Xerosis | 76 | 89.1 70.7–112.4ROR 89.6 · χ² 6,125 / p <1e-300 | 81.9 EB05 67.6 · IC025 +5.4 3/3 methods agree | Labeled adverse reaction exact term | serious n=76 · 96% clinician | not reported in cached trials |
| Hypomagnesaemia | 828 | 85.5 79.8–91.5ROR 90.2 · χ² 64,900 / p <1e-300 | 80.2 EB05 75.7 · IC025 +6.1 3/3 methods agree | Not in label — unassessed | serious PRR 48.3 · 93% clinician | NCT02089737: 10/1,831 (0.5%) on Panitumumab (serious AE) |
| Mucosal toxicity | 16 | 84.0 50.7–139.1ROR 84.1 · χ² 1,157 / p 7e-254 | 72.5 EB05 47.3 · IC025 +3.7 3/3 methods agree | Labeled (related wording) related wording | serious n=16 | not reported in cached trials |
| Acne pustular | 48 | 83.7 62.6–112.1ROR 84.0 · χ² 3,614 / p <1e-300 | 76.5 EB05 60.0 · IC025 +5.0 3/3 methods agree | Labeled (related wording) related wording | serious n=46 | not reported in cached trials |
| Adenocarcinoma of colon | 107 | 81.5 67.1–99.0ROR 82.1 · χ² 7,942 / p <1e-300 | 75.8 EB05 64.5 · IC025 +5.5 3/3 methods agree | Not in label — unassessed | serious n=107 · 98% clinician | not reported in cached trials |
| Ectropion | 19 | 81.1 51.1–128.9ROR 81.2 · χ² 1,342 / p 4e-294 | 71.2 EB05 48.2 · IC025 +3.9 3/3 methods agree | Not in label — unassessed | serious n=18 | not reported in cached trials |
| Colon cancer metastatic | 83 | 73.4 58.9–91.5ROR 73.8 · χ² 5,547 / p <1e-300 | 68.5 EB05 57.0 · IC025 +5.3 3/3 methods agree | Not in label — unassessed | serious n=83 | NCT00339183: 2/587 (0.3%) on Panitumumab (serious AE) |
| Growth of eyelashes | 41 | 73.1 53.4–100.0ROR 73.3 · χ² 2,695 / p <1e-300 | 67.2 EB05 51.7 · IC025 +4.7 3/3 methods agree | Labeled adverse reaction exact term | serious n=30 | not reported in cached trials |
| Metastases to ovary | 16 | 71.5 43.3–118.3ROR 71.6 · χ² 990 / p 1e-217 | 63.1 EB05 41.2 · IC025 +3.6 3/3 methods agree | Not in label — unassessed | serious n=16 | not reported in cached trials |
| Liver operation | 15 | 69.9 41.6–117.4ROR 69.9 · χ² 903 / p 1e-198 | 61.5 EB05 39.6 · IC025 +3.5 3/3 methods agree | Reporting / coding artifact | serious n=15 | NCT00339183: 1/594 (0.2%) on Panitumumab (serious AE) |
| Carcinoembryonic antigen increased | 93 | 68.1 55.3–83.8ROR 68.5 · χ² 5,786 / p <1e-300 | 64.0 EB05 53.8 · IC025 +5.3 3/3 methods agree | Lab value / disease marker | serious n=88 | not reported in cached trials |
| Rectal adenocarcinoma | 27 | 63.7 43.3–93.7ROR 63.8 · χ² 1,530 / p <1e-300 | 58.4 EB05 42.2 · IC025 +4.2 3/3 methods agree | Not in label — unassessed | serious n=27 · 100% clinician | not reported in cached trials |
| Rash pustular | 326 | 62.7 56.2–70.0ROR 64.1 · χ² 18,858 / p <1e-300 | 59.7 EB05 54.5 · IC025 +5.6 3/3 methods agree | Labeled adverse reaction exact term | serious n=307 | not reported in cached trials |
| Carbohydrate antigen 19-9 increased | 20 | 54.0 34.5–84.4ROR 54.0 · χ² 949 / p 1e-208 | 49.6 EB05 33.9 · IC025 +3.8 3/3 methods agree | Lab value / disease marker | serious n=20 · 100% clinician | not reported in cached trials |
| Catheter site thrombosis | 10 | 51.9 27.6–97.5ROR 51.9 · χ² 432 / p 2e-96 | 45.9 EB05 26.6 · IC025 +2.8 3/3 methods agree | Not in label — unassessed | serious n=10 | NCT00339183: 1/587 (0.2%) on Panitumumab (serious AE) |
| Dermatitis infected | 18 | 50.3 31.4–80.5ROR 50.4 · χ² 791 / p 2e-174 | 46.3 EB05 31.0 · IC025 +3.6 3/3 methods agree | Not in label — unassessed | serious n=17 | not reported in cached trials |
| Therapy partial responder | 463 | 42.7 39.0–46.8ROR 44.0 · χ² 18,235 / p <1e-300 | 41.3 EB05 38.3 · IC025 +5.2 3/3 methods agree | Reporting / coding artifact | serious PRR 32.7 · 99% clinician | not reported in cached trials |
| Pyogenic granuloma | 13 | 38.8 22.4–67.3ROR 38.8 · χ² 429 / p 1e-95 | 35.9 EB05 22.3 · IC025 +3.1 3/3 methods agree | Not in label — unassessed | serious n=12 | not reported in cached trials |
| Gene mutation | 54 | 37.6 28.7–49.3ROR 37.7 · χ² 1,835 / p <1e-300 | 36.2 EB05 28.8 · IC025 +4.3 3/3 methods agree | Labeled (related wording) related wording | serious n=51 · 98% clinician | not reported in cached trials |
| Metastases to pelvis | 17 | 37.2 23.0–60.3ROR 37.3 · χ² 549 / p 1e-121 | 35.0 EB05 23.1 · IC025 +3.4 3/3 methods agree | Not in label — unassessed | serious n=17 | not reported in cached trials |
| Metastases to peritoneum | 65 | 35.9 28.0–45.8ROR 36.0 · χ² 2,111 / p <1e-300 | 34.6 EB05 28.1 · IC025 +4.4 3/3 methods agree | Not in label — unassessed | serious n=65 · 95% clinician | not reported in cached trials |
| Metastases to liver | 432 | 34.0 30.9–37.4ROR 34.9 · χ² 13,468 / p <1e-300 | 33.1 EB05 30.6 · IC025 +4.8 3/3 methods agree | Not in label — unassessed | serious PRR 22.0 | NCT02089737: 1/1,254 (0.1%) on Panitumumab (serious AE) |
| Hypertrichosis | 44 | 32.5 24.1–43.9ROR 32.6 · χ² 1,282 / p 5e-281 | 31.4 EB05 24.3 · IC025 +4.1 3/3 methods agree | Not in label — unassessed | serious n=43 | not reported in cached trials |
Trial evidence (ClinicalTrials.gov)
✓ Trial adverse-event data found on ClinicalTrials.gov
Largest completed trials with posted results that list Panitumumab as a study intervention. The right-hand column of the signal table shows whether each FAERS term was also recorded in these trials, with a real denominator (10 of 40 signal terms matched).
- NCT02089737 — Panitumumab for Intravenous Infusion 100 mg and 400 mg Special Drug Use Surveillance "Survey on Unresectable, (N=3091, phase n/a; 217 AE terms posted; arms: Panitumumab; Concomitant Administration of Panitumuma)
- NCT00339183 — Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone (N=1186, PHASE3; 330 AE terms posted; arms: Panitumumab Plus FOLFIRI; FOLFIRI Alone)
Caveats: trial populations, doses and follow-up differ from the reporting population; AE terms are sponsor-coded and matched here by wording; absence from a trial list means the term was not reported above the sponsor's frequency threshold, not that it cannot occur.
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Rash | 1,876 | 5.8 5.6–6.1ROR 6.5 · χ² 7,658 / p <1e-300 | 5.8 EB05 5.6 · IC025 +2.5 3/3 methods agree | Labeled — boxed warning exact term | serious PRR 6.4 | NCT02089737: 1/1,831 (0.1%) on Panitumumab (serious AE) |
| Diarrhoea (diarrhea) | 1,614 | 3.4 3.2–3.5ROR 3.7 · χ² 2,788 / p <1e-300 | 3.4 EB05 3.2 · IC025 +1.7 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 3.7 | NCT02089737: 26/1,831 (1.4%) on Panitumumab (serious AE) |
| Dermatitis acneiform | 1,048 | 282.6 264.9–301.5ROR 302.9 · χ² 242,298 / p <1e-300 | 232.2 EB05 220.6 · IC025 +7.6 3/3 methods agree | Labeled adverse reaction exact term | serious n=965 · 95% clinician | NCT02089737: 14/1,831 (0.8%) on Panitumumab (serious AE) |
| Death | 994 | 1.6 1.5–1.7ROR 1.6 · χ² 204 / p 1e-46 | 1.6 EB05 1.5 · IC025 +0.5 | Outcome field, not a reaction boxed warning mentions mortality | serious PRR 1.0 | NCT02089737: 4/1,831 (0.2%) on Panitumumab (serious AE) |
| Neutropenia (low neutrophils (infection-fighting cells)) | 929 | 9.3 8.7–9.9ROR 9.8 · χ² 6,861 / p <1e-300 | 9.2 EB05 8.7 · IC025 +3.1 3/3 methods agree | Not in label — unassessed | serious PRR 6.3 · 95% clinician | NCT02089737: 17/1,831 (0.9%) on Panitumumab (serious AE) |
| Skin toxicity | 906 | 261.5 244.0–280.3ROR 277.6 · χ² 196,266 / p <1e-300 | 217.6 EB05 206.0 · IC025 +7.5 3/3 methods agree | Labeled adverse reaction exact term | serious n=840 | NCT00339183: 3/587 (0.5%) on Panitumumab (serious AE) |
| Nausea | 838 | 1.4 1.3–1.5ROR 1.5 · χ² 112 / p 2e-26 | 1.4 EB05 1.4 · IC025 +0.4 | Labeled adverse reaction exact term | serious PRR 1.7 | NCT02089737: 5/1,831 (0.3%) on Panitumumab (serious AE) |
| Hypomagnesaemia | 828 | 85.5 79.8–91.5ROR 90.2 · χ² 64,900 / p <1e-300 | 80.2 EB05 75.7 · IC025 +6.1 3/3 methods agree | Not in label — unassessed | serious PRR 48.3 · 93% clinician | NCT02089737: 10/1,831 (0.5%) on Panitumumab (serious AE) |
| Colorectal cancer metastatic | 768 | 684.4 628.2–745.6ROR 719.8 · χ² 345,403 / p <1e-300 | 446.9 EB05 421.0 · IC025 +8.3 3/3 methods agree | Likely indication confounding term in indications | serious n=768 | NCT00339183: 9/587 (1.5%) on Panitumumab (serious AE) |
| Disease progression | 725 | 8.3 7.8–8.9ROR 8.7 · χ² 4,662 / p <1e-300 | 8.2 EB05 7.8 · IC025 +2.9 3/3 methods agree | Reporting / coding artifact | serious PRR 5.7 | not reported in cached trials |
| Neuropathy peripheral (nerve damage in hands/feet) | 724 | 10.4 9.7–11.2ROR 10.8 · χ² 6,111 / p <1e-300 | 10.3 EB05 9.7 · IC025 +3.2 3/3 methods agree | Not in label — unassessed | serious PRR 7.8 · 92% clinician | NCT02089737: 1/1,831 (0.1%) on Panitumumab (serious AE) |
| Fatigue (tiredness) | 694 | 1.2 1.1–1.3ROR 1.2 · χ² 24 / p 4e-7 | 1.2 EB05 1.1 · IC025 +0.1 | Labeled adverse reaction exact term | serious PRR 1.3 | NCT02089737: 2/1,831 (0.1%) on Panitumumab (serious AE) |
| Off label use (used outside approved label) | 686 | 1.1 1.0–1.1ROR 1.1 · χ² 3 / p 0.049 | 1.1 EB05 1.0 · IC025 -0.0 PRR-only: not supported by EBGM or IC | Reporting / coding artifact | serious PRR 1.1 | not reported in cached trials |
| Dry skin | 656 | 6.7 6.3–7.3ROR 7.0 · χ² 3,207 / p <1e-300 | 6.7 EB05 6.3 · IC025 +2.6 3/3 methods agree | Labeled — boxed warning exact term | serious PRR 17.9 | NCT02089737: 1/1,254 (0.1%) on Panitumumab (serious AE) |
| Vomiting | 643 | 1.8 1.7–2.0ROR 1.9 · χ² 255 / p 1e-57 | 1.8 EB05 1.7 · IC025 +0.8 | Labeled adverse reaction exact term | serious PRR 1.7 | NCT02089737: 5/1,831 (0.3%) on Panitumumab (serious AE) |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Trichomegaly — n=35, PRR 815.3
- Hepatectomy — n=28, PRR 136.2
- Hypomagnesaemia — n=828, PRR 85.5 (also seen in trial arm)
- Adenocarcinoma of colon — n=107, PRR 81.5
- Colon cancer metastatic — n=83, PRR 73.4 (also seen in trial arm)
- Rectal adenocarcinoma — n=27, PRR 63.7
- Metastases to peritoneum — n=65, PRR 35.9
- Metastases to liver — n=432, PRR 34.0 (also seen in trial arm)
- Hypertrichosis — n=44, PRR 32.5
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Panitumumab?
In FDA FAERS, the most frequently co-reported reaction terms for Panitumumab are rash, diarrhoea, dermatitis acneiform, neutropenia, skin toxicity, nausea. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Panitumumab have an FDA boxed warning?
Yes. The current FDA label carries a boxed warning: DERMATOLOGIC TOXICITY Dermatologic Toxicity: Dermatologic toxicities occurred in 90% of patients and were severe (NCI-CTC Grade 3 and higher) in 15% of patients receiving Vectibix monotherapy [see Dosage and Administration (2.3) , Warnings and Precautions (5.1) and Adverse Reactions (6.1) ] .
Do FAERS signals prove that Panitumumab causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID e0fa4bca-f245-4d92-ae29-b0c630a315c2, effective 20260623; matched on
openfda.generic_name.exact:"PANITUMUMAB") - Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,020 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
PANITUMUMAB, results-bearing studies sorted by enrollment)
Page generated 2026-10-08. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.